KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS
Clinical trials for KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS explained in plain language.
Never miss a new study
Get alerted when new KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS trials appear
Sign up with your email to follow new studies for KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Breakthrough drug may give kidney transplants to those previously turned away
Disease control CompletedThis study tested a drug called imlifidase in 64 people with very high antibody levels (cPRA ≥99.9%) who were waiting for a kidney transplant. The goal was to see if imlifidase could help them receive a kidney from a deceased donor and improve kidney function after one year compa…
Matched conditions: KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 17, 2026 01:12 UTC
-
Breakthrough drug may give hope to kidney patients rejected for transplant
Disease control CompletedThis study tested a drug called imlifidase in 113 highly sensitized kidney patients who had a positive crossmatch against a deceased donor. The drug was given before transplant to reduce the risk of rejection. The main goal was to see how many patients still had a working kidney …
Matched conditions: KIDNEY TRANSPLANTATION IN HIGHLY SENSITIZED PATIENTS
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC